Shiyao Group (1093.HK): Harvesting impacts fully absorb star products to maintain their potential, innovation and transformation will enter a period of intensive harvesting
Shi Pharmaceutical (1093.HK): Innovative drugs drive steady growth in proprietary pharmaceutical business revenue, and API prices are expected to stabilize
CSPC Group (1093.HK): Revenue is expected to resume double-digit growth in 2024
CSPC Group (1093.HK): Performance is in line with expectations and is expected to grow by double digits in 2024
CSPC Group (01093.HK): Steady growth in performance, innovation and internationalization have been realized one after another
CSPC PHARMACEUTICAL(1093.HK):4Q RESULTS MISSED; OPTIMISTIC 2024 GUIDANCE OF DOUBLE-DIGIT GROWTH
Goldman Sachs: The target price for the “buy” rating of CSPC (01093) was raised to HK$9.73
CSPC Group (1093.HK): Stable annual results, driven by eight major innovation platforms
CSPC Group (01093.HK): Steady performance, expected double-digit increase in revenue and profit in 2024
CSPC Group (1093.HK): 2023 is in line with expectations, maintaining the 2024 double-digit growth rate guidelines, and sales of new products are gradually improving
Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.41 From HK$8.98, Keeps at Buy
Nomura: Maintaining CSPC Group's (01093) “Buy” rating and raising the target price to HK$9.41
CSPC Group (1093.HK): New Novartis acquires key asset subsidiaries within the Group to further strengthen collaboration; maintain purchases
CSPC Group (1093.HK): Innovative drug research and development is rapidly advancing, and performance is about to resume rapid growth
Bank Ratings丨Daiwa: Shengshi Pharmaceutical Group (1093.HK) has a target price of HK$7.6, maintaining an outperforming market rating
Shiyao Pharmaceutical Group (1093.HK): Neural sector maintains high growth and new product release can be expected
Shiyao Pharmaceutical Group (01093.HK): Integrated implementation of innovative assets in line with expectations in the 3rd quarter
Shiyao Pharmaceutical Group (1093.HK): 3Q23 performance is basically in line with expectations, revenue growth is expected to rebound to double digits in 2024
Shiyao Pharmaceutical Group (1093.HK): Innovative drug pipelines enrich performance and steady growth
Shiyao Pharmaceutical Group (1093.HK): Bank of China Bank International's 2023 Medical Industry Enterprise Daily Report
No Data